Maze Therapeutics, Inc., a biopharmaceutical company focused on developing precision medicines for renal, metabolic, and cardiovascular diseases, announced that CEO Jason Coloma, Ph.D., will present a ...
In other recent news, Maze Therapeutics has been the focus of significant analyst attention following promising Phase 1 data for its lead drug candidate, MZE782. H.C. Wainwright raised its price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results